{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"An event was considered DLT if it occurred within 21 days of treatment and met any of the following criteria within same period:\n\n* Any Grade (Gr.) 3 or greater non-hematologic toxicity as described in NCI-CTCAE Version 5.0, other than corneal events that persists for \\>48 hours despite supportive treatment or leads to hospitalization.\n* Hematologic toxicity such as Gr. 3 or greater febrile neutropenia lasting \\>48 hours despite adequate treatment (Gr. 3 defined as absolute neutrophil count (ANC) \\<1000/millimeter cube (mm\\^3) at a single temperature \\>38.3 degree celsius or a sustained temperature \\>=38 degree celsius for more than 1 hour) and, Gr. 4 thrombocytopenia defined as platelet count \\<25000/mm\\^3 with clinically significant bleeding, or if platelet transfusion is required.\n* Gr. 4 per the corneal grading scale.\n* Liver toxicity meeting pre-specified by GSK liver stopping criteria.","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) were administered with 2.5 milligram per kilogram (mg/kg) belantamab mafodotin intravenous (IV) infusion over 30-60 minutes on day 1 of each 21-days cycle. Participants were treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.","id":"OG000","title":"Belantamab Mafodotin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT evaluable population included all the eligible participants who have received the 1st dose as planned and experienced a DLT during the cycle 1 or completed the cycle 1.","reportingStatus":"POSTED","timeFrame":"Day 1 to day 21 of cycle 1","title":"Number of Participants With Dose Limited Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}